Wednesday, June 10, 2026

pharma Β· Neurogenic Detrusor Overactivity

Astellas Pharma

Astellas Pharma clinical programs β€” 1 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

JP HQ
12,378 Employees
EMA registrant Type
Company details
Intelligence Β· Clinical Programs

Astellas Pharma projects

1 ClinicalTrials.gov programs sponsored by Astellas Pharma.

Astellas Pharma has 1 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Solifenacin succinate

    Astellas Pharma Europe B. V.

    Neurogenic Detrusor Overactivity

    phase 3 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Astellas Pharma have?

1 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.